Mutations in MHC-I, along with gradual upregulation of MHC-I on various cell types throughout disease progression are associated with increased risk for MS and may also contribute to the increased ratio of CD8 to CD4 T cells in MS brain lesions (138). Here, CD8A is linked to myeloid sarcoma.